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AI CAR - 5-amino-4-imidazolecarboxamide ribonucleotide 
d TMP - thymidylic acid 
dUMP - deoxyuridylic acid 
DHP - dihydrofolic acid 
FGAR - formylglycinamide ribonucleotide 
FIGLU - formiminoglutamic acid 
5-MeTHE - 5-methyltetrahydrofolic acid 
GAR - glycinamide ribonucleotide 
IMP - inosinic acid 
MTX - Methotrexate (amethopterin) 
p-ABG - para-aminobenzoylglutamate 





Several coenzyme forms of folic acid 
(pteroylmonoglutamatic acid) have been described in 
recent years. These coenzymes are one-carbon adducts 
of THE, the fully reduced form of folic acid. In 
each case it has been found that the one-carbon 
S 10 
adducts are carried on either the IP or N position, 
or both, and are at the methyl, formate, or 
formaldehyde oxidation states. TABLE I summarizes 
the one-carbon adducts of the various coenzyme forms 
of folic acid that have been described, figure 1 
compares the structures of the parent compound 
and one coenzyme form, 5-MeTHF. 
These folate coenzymes are involved in a 
variety of reactions. They are required for the 
biosynthesis of nucleic acid precursor units, in 
particular for the synthesis of the purine ring 
(10-formylTHF and 5510-methenylTHE) and of thymidylic 
acid (5,10-methyleneTHF). The parent compound THE 
participates in the catabolism of histidine and the 
interconversion of serine and glycine. The 5-MeTHE 
form is required for the methylation of homocysteine 
to yield methionine. 
All of the folate coenzymes are inter¬ 
related. As each coenzyme donates its one-carbon 
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TABLE I. The coenzyme forms of folic acid (pteroylmonoglutamic 
acid) and their one-carbon adducts. (1) 
Adduct Oxidation State 
5-formylTHE -CHO formate 
10-formylTHF -CHO formate 
5-formininoTHE -GH=MH formate 
5,10-methenylTHE >CH formate 
5,10-methyleneTHE >ch2 formaldehyde 
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Figure 1. Structural relationship between folic 
acid and 5-MeTHF. 
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adduct, THF is regenerated in all but one reaction - 
the biosynthesis of thymidylate from deoxyuridylate. 
It has been found (2) that the folate coenzyme involved 
in this last named reaction is 5,10-methyleneTHF. This 
reaction requires the simultaneous donation of a 
hydroxymethyl group and of two protons from the THF 
to form the thymine methyl. Thus, DHF, rather than 
THF, is produced. The enzyme dihydrofolate reductase 
then regenerates THF. Alternately, 5,10-methyleneTHF 
may be converted to 5,10-methenylTHF or 5-MeTHF. 
The interconversion of the folate coenzymes are 
presented in Figure 2. 
Once the THF molecule has been produced, 
there are at least three pathways by which it may 
gain a one-carbon adduct. 
The first possibility is associated with the 
catabolism of histidine, THF may react with the 
formimino group of FIGLU; this group is transferred 
to the 5 position of THF as a one-carbon fragment and 
is then able to enter into the one-carbon pool (3,4). 
(Equations 1 and 2). Because of the dependency of FIGLU 
metabolism on available stores of THF, an Increase of 
FIGLU in the urine may be evidence of folate deficiency. 
formimino-L-glutamic acid + THF - - -. 
5-formiminoTHF + L-glutamic acid (1) 
5-formiminoTHF ~-'-V —±r 5,10-methenylTHF + (2) 
A second way in which THF can act as an acceptor 
for a one-carbon fragment is by transfer of the beta carbon 
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Figure 2. The relationships which exist between the 
major folate coenzymes in mammalian systems. Modified 
from Buchanan ( 5 ). 

6. 
of serine to yield 5,10-methyleneTHF and glycine. (Equation 3) 
Serine + THF =y- glycine + 5,10-methyleneTHF (3) 
The third pathway by which THP may gain a 
one-carbon adduct is by direct formylation of THP, 
catalyzed by the enzyme THP formylase. (Equation 4) 
HCOOH + ATP + THP r-hr 10-formylTHF + ADP + Pi (4) 
5-MeTHF 
Historically, 5-MeTHF, the last folate 
coenzyme to have been described, was first isolated 
as "prefolic A" from horse liver (6) and from E. Coli (7); 
in the latter circumstance as an intermediate in the 
biosynthesis of methionine from homocysteine. This 
coenzyme is a major folate compound in the serum (8) 
and liver (9)» 
The pathways involved in methionine biosynthesis 
utilizing 5-MeTHF and vitamin are illustrated in 
Figure 3. Although, in certain bacteria, an alternate 
pathway for methionine biosynthesis not requiring a 
vitamin B^ coenzyme may exist, in mammalian tissue, 
evidence indicates that the methylation of homocysteine 
requires vitamin Bcoenzyme as well as 5-MeTHF. 
RELATIONSHIP BETWEEN FOLIO ACID, VITAMIN B12» AND 
MEGALOBLASTOSIS 
Clinically a deficiency of either B^ or folic 
acid may produce a megaloblastic anemia. Marshall and 
Jandl (10) made the important observation that patients 













5 - MeTHF 
•*“*» FAD 
homocysteine 
(a) serine hydroxymethyltransferase 
(b) 5,10-methyleneTHF reductase 
(c) 5-methyltetrahydrofolate-homocysteine methyltransferase 
B12 coenzyme essential cofactor 
Figure 3. Relationship of methionine biosynthesis, 
folic acid, and vitamin B^. Modified from Buchanan ( 5 )• 

8. 
responded to physiologic (0.4 mgm) doses of folic acid, 
but that B deficient patients gave no response to this 
12 
dose. They further noted that B12 deficient patients 
did respond to much greater (pharmacologic) doses of 
folic acid (15 mgm); folate deficient patients responded 
as well to the smaller dose as to the larger dose. 
The most widely accepted hypothesis for the 
interrelationships of folic acid and vitamin B-^2 in 
hemopoiesis is that lack of vitamin B^2 causes the 
available folates to become "trapped" as the 5-MeTHF 
form (11), since 5-MeTHF is able to proceed to THF 
only after the B^-clependent methylation of homocysteine. 
Since the equilibrium for the formation of 5-MeTHF from 
5,10-methyleneTHF lies far in the direction of the 
formation of 5-MeTHF, the diversion of large amounts 
of folates into the 5-MeTHF form would reduce the 
availability of the other folate forms which are 
required for the synthesis of nucleic acids. This may 
explain those clinical signs of folate deficiency which 
result from B-^2 deficiency. 
This hypothesis is not universally accepted. 
Beck (12) has proposed an alternative hypothesis to 
explain the megaloblastic hemopoiesis that occurs in B^2 
deficiency. In L. leichmanii coenzyme B-^2 is required for 
the reduction of ribose nucleotides to deoxyribose 
nucleotides, the precursors of DM; however, the 
enzyme catalyzing this reduction in E. Coli does not 
require B^2• The participation of vitamin B^2 in this 
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conversion has not been established for mammalian 
systems, but Beck proposes that it is required for 
hemopoiesis and that, under conditions of B-^ deficiency, 
limitation of this pathway may be significant for the 
megaloblastic hemopoiesis. 
PLASM AND URINE FOLATES 
Spray et al. (13) noted in 1951 that compared 
to the situation in normal subjects, there was a more 
rapid plasma disappearance of exogenously administered 
folic acid in patients with megaloblastic anemia due to 
folic deficiency. This rapid disappearance was again 
noted in 1961 by Metz et al. (14) who also reported a 
faster plasma disappearance of injected folic acid in 
vitamin B-^ deficient patients than in normal subjects. 
Later studies (15) suggested two phases of 
plasma disappearance of folic acid. The first phase 
could be explained by a rapid uptake by the tissues. 
It was suggested that the prolonged second phase con¬ 
sisted of removal of folate from the plasma into the 
urine after the tissues had been saturated. 
Johns et. al. (16) employing labeled folic 
acid demonstrated that plasma disappearance was related 
to the dose. When small doses of folic acid (1 ug/kg) 
were injected, the plasma disappearance was rapid and 
urinary excretion was slight. By increasing the dose 
(to 15 ug/kg and up to 150 ug/kg), the plasma disappearance 
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was relatively slower and urinary excretion accounted 
for a much larger percent of the folate removed. 
With small doses or in folate deficient tissues, 
tissue uptake plays a much more important role than 
with larger doses or greater tissue saturation. 
By displacement studies with unlabeled folic 
acid it was also shown that, although folic acid is 
quickly removed from the plasma and accumulated within 
the tissues, it is only slowly converted to a non- 
displaceable form. 
Condit and Grob (1?) have reported that 99% 
of endogenous filtered folic and folinic acids are 
reabsorbed by the kidney; but if the plasma concentra¬ 
tion was increased to 100-500 times greater than the 
physiological level, only 50^ of the filtered load 
was reabsorbed. 
Chanarin and Bennett (18) studied the 
importance of renal clearance for folic acid. Normal 
patients and patients with impaired renal function 
were given folic acid intravenously. As expected, 
those with impaired kidney function had high serum 
folate levels for longer periods of time than did 
normals. The same study by Chanarin et al. indicated 
a direct relationship between the serum folic acid 
level and the renal excretion of folic acid. 
Goresky ejb al. (19) substantiated the findings 
that folic acid is actively reabsorbed from the kidney 
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■tubules and suggested that exogenously administered 
folic acid is stored within these tubule cells until 
metabolized. After being metabolized, it is slowly 
released into the blood. Further, these authors 
showed that MTX inhibits folic acid reabsorption. 
MET HO T RE XA TE (AMETHOPTERIN) 
Methotrexate (KTX) is a potent folic acid 
antagonist which acts by competitive inhibition of 
the enzyme dihydrofolate reductase. Structurally, 
MTX is 4-amino-4-deoxy-M'I'0-methyl-folic acid. It 
has been used successfully in conditions such as 
acute leukemia in children, choriocarcinoma, mycosis 
fungoides, psoriasis, and carcinomas of the breast, 
tongue, pharynx and testes. 
Swenseid et. al. (20) found that aminopterin 
increased the urinary excretion of folic acid. 
Condit and Grob (17) reported a decrease in 
the renal tubular reabsorption and decreased extrarenal 
uptake (normally mainly by the liver) of injected folic 
acid after aminopterin administration. It appeared 
as though there was a decrease in the intracellular 
transport and utilization of folic acid, and that both 
the renal tubules and the extrarenal sites were affected. 
Johns et. al. (21) (22) suggested that MTX 
might compete for the folate transport system. If a 
patient was preloaded with MTX, the 24 hour urinary 
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excretion of injected folic acid was about three times 
greater than in non-preloaded patients. If patients 
were preloaded with folic acid rather than MTX, similar 
results were obtained. If the experiment was reversed 
so that patients were preloaded with labeled folic 
acid, about seven times more of this label could be 
flushed out if folic acid was administered rather 
than MTX. It appeared as if MTX was able to compete 
with the transport system Into cells but was able to 
enter the cell only slowly if at all. 
More recent work (23) again Indicated that 
MTX was only slowly transported into cells and that 
the fully reduced compounds (tetrahydro ) were less 
effective in displacing MTX than the unreduced 
(pteroylglutamate) and partially reduced (dihydro) 
compounds. Of all compounds studied, MTX was the 
most effective displacing agent for retained MTX. 
It has been well known that MTX inhibits 
the enzyme dihydrofolate reductase by binding very 
tightly to it (24). More recently, Goldman, et al. 
(25) have suggested that MTX may also be distributed 
into two pools other than that bound to dihydrofolate 
reductase. The first has a low affinity for sites 
which are located on or near the surface of the cell 
membrane. The affinity Is still present at 0°C, and 
is weakly inhibited by structural analogues. It is 
believed not to be related to the transport process. 
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The second is as a rapidly exchangeable intracellular 
pool. This pool is believed to exist unbound within 
the cells. The third and final pool is that which 
is bound tightly intracellularly to the enzyme 
dihydrofolate reductase. 
Furthermore, it appears as if a transport 
system exists -- with structural requirements for a 
substrate similar to but different from the ideal 
substrate of dihydrofolate reductase. Using Ehrlich 
ascites carcinoma and L 1210 cells, Kessel and Hall (26) 
found that folinic acid competed with MTX for transport 
into these cells, 
CHROMATOGRAPHY 
It has long been recognized that there are 
several physiologically-occurring folate coenzymes. 
Because of the low levels of the coenzymes and the 
lack of a sensitive chemical assay, in the past these 
compounds have been identified by microbial assay. 
The growth requirements of folic acid assay organisms 
have been reviewed by Stokstad (27), and they are 
presented in TABLE II. 
Although the microbial assay is very sensitive, 
it is not without problems. The results of the L. 
easel assay may vary 100 fold depending upon the 
treatment of the sample (28). The specific factors 
found to influence the results were the presence of 
reducing agents (29); the temperature and conditions 
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TABLE II. Relative activity of various derivatives 
of folic acid for the support of growth of the commonly- 










coccus bacillus clavin g (Aseptic hymena 
Compound faecalis casei Method T Addition) geleii 
Folic acid (PtGlu) 
(a) 
+ + -(b) ca, + 
Pteroyldiglutamic acid + + - 
Pteroyltriglutamic acid - + - + 
Pteroylheptaglutamic acid - - - + 
H4PtGlu + + + 
5-0H0—H4PtGlu + + + + 
10-CH0--H4PtGlu + + + 
5,10-CH=Il4PtGlu + + + 
5-CH3--H4PtGlu - + “ 




Plus indicates activity of 70-100% of folic acid 
on a molar basis for S.faecalis, Lactobacillus 
casei, and T.geleii, and 70-100% of 5~ formylTH^ 
5%- 
for Leuconostoc citrovorum. 
(b) 
Minus indicates activity of less than 
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of storage of the sample (30); the presence of 
monoglutamate or polyglutamate derivatives (11); and 
even the disease entity of the patient upon whom the 
assay is being performed (31). Also, various growth 
requirements for the bacteria used in the microbial 
test have been reported within the literature. 
The method of identification used in these 
experiments is column chromatography and is not 
dependent upon these variables. One of the first 
attempts at chromatography was by Usdin et al. (32). 
With paper chromatography he was able to separate at 
least six substances which supported the growth of 
the assay organisms. All of these had high L.casei 
activity, low S. faecalis activity, and even lower 
L. citrovorum activity. 
Most of the naturally occuring blood 
folates later identified by Usdin with TEAE-Cellulose 
were formylated or reduced and formylated (33). 
Their number then varied between nine and eleven. 
The derivative 5-MeTHE was not listed within this 
group, apparently unknown at that time. 
In 1961, Larrabee et al. (34) reported a 
compound in E. coli required for the methylation of 
homocysteine. This compound was identified as 5-MeTHE. 
Subsequently, Horonha and Silverman (35) reported 
at least four 5-MeTHE polyglutamates using DEAB- 
Cellulose. 
I 
A similar chromatographic system to that 
used in these experiments has been found to elute 
the folate derivatives in the following order: (36) 
N10 - formyl THE1 
N10 - formylDHF 







Ghromatography thus enables one to identify 
an unknown radiolabeled eoenzyme by its elution 




The purpose of these studies was to 
determine the rate at which physiologic doses of 
exogenously administered 5-MeTHF is normally 
metabolized and excreted in man, and how these para¬ 
meters are affected by a potent antifolate, MTX. 
In order to measure the metabolism and 
disposition of 5-MeTHF, a doubly labeled radioactive 
molecule of 5-MeTHE was prepared. This molecule 
was labeled with tritium in the 3* and 5' positions 
of the benzene ring of the parent molecule and also 
with carbon-14 at the labile 5-methyl position. In 
this manner, metabolism of the 5-methyl carbon was 
followed separately to that of the folate molecule. 
The fate of this compound was determined 
in samples of plasma and urine which were collected 
at various times after each administration of 
5-MeTHF — both before and after MTX therapy. To 
identify the (new) folate compounds which were 
radiolabeled, and to determine the ratio of the 
radiolabels present in these compounds, representative 
samples of urine and serum were chromatographed. 
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METHODS AND MATERIALS 
PREPARATION OF DOUBLY-LABELED 5-MeTHF 
Preparations of 5-MeTHF were obtained 
through the courtesy of Dr. P. P. Nixon. The 
preparations were either unlabeled or radiolabeled 
with carbon-14 on the 5-methyl group or with tritium 
at the 3', 51 position of folic acid. 
The specific activities of the tritium 
and carbon-14 were 250 and 12 microcuries per 
micromole respectively. 
The samples were dissolved in 0.7% sodium 
ascorbate, diluted with physiologic saline, filtered 
through millipore filters and pyrogen tested. 
PATIENTS 
Two patients were studied in detail both 
before and after MTX therapy. Patient 1: 51 year 
old male suffering from reticulum cell sarcoma of 
the skin. Patient 2: 56 year old male suffering 
from carcinoma of the head and neck. 
ADMINISTRATION OF 5-MeTHF AND MTX 
A dose of 5 microgram/Kg of 5-MeTHF was 
administered intravenously both before and after MTX 
therapy. Patient 1: MTX therapy was a 24 hour 
2 
infusion at 120 mg/meter". Readministration of 
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5-MeTHF followed the completion of MTX therapy Toy 
48 hours. Patient 2: MTX therapy was a 36 hour 
p 
infusion at 120 mg/me ter"1. Readministration of 
5-MeTHF followed the completion of MTX therapy by 
24 hours. 
COLLECTION 0? PLASMA, SERUM AMD URINE 
Blood samples were collected in EDTA. 
The cells were separated by centrifugation and the 
plasma was removed and refrigerated. 
For serum, large {50-100 ml) blood 
collections were drawn at the appropriate times, 
clot formation was allowed, and the serum was 
recovered after centrifugation. Sufficient 2- 
mercaptoethanol was added to the serum to achieve a 
concentration of 0.5 M. The serum samples were then 
frozen until chromatographed. 
Urine samples were collected at intervals 
and stored in containers. Ten ml of 2-mercaptoethanol 
were added for the preservation of the reduced folates. 
The samples -were refrigerated until chromatographed. 
CHROMATOGRAPHY 
Chromatography of samples was through 
A-25 DEAE-Sephadex (Pharmacia, Inc.) packed in 
0.9 x 27 cm. columns. Known samples of THE, 
5-formylTHF and jd-ABG were added to the columns 
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with the sample to serve as markers. The columns 
were eluted by potassium phosphate buffer, pH 6.0, 
the concentration of which was increased in a linear 
gradient from 0,1 M to 0.8 M, and which was previously 
gassed with nitrogen and contained 0.2 M 2-mercaptoethanol. 
The gradient was constructed from 250 ml of each of 
0.1 M and 0.8 M solutions arranged so that the 
concentration began with 0,1 M potassium phosphate 
and linearly increased until it approached 0.8 M 
potassium phosphate. Constant volume fractions in 
the range of 3 to 5 ml were collected. The eluant 
fractions were analyzed both by fluorometry and by 
radioactive counting. 
Fluorometric analysis was employed because 
of sensitivity and selectivity. The excitation 
wavelength was set at 305 myi, the emission was 
measured at 360 mu, and fluorescence was measured 
at pH 3 and pH 6, At these chosen wavelengths, 
THF has a greater fluorescence at pH 3 than at 
pH 6, £-ABG has a slightly greater fluorescence at 
pH 6 than at pH 3, and 5-formylTHF has slightly 
greater fluorescence at pH 3 than at pH 6. Since 
the samples were already at pH 6, after reading at 
that pH, glacial acetic acid was used to reduce the 
pH to 3. By combining this analysis with radioactivity 
counting, the radioactive compounds could be 
identified by their elution characteristics in 
reference to the known markers. 
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The relative positions in which the folate 
derivatives elute in this system has been determined (37), 
Figure 4 is an idealized elution pattern obtained 
from the chromatography of the folate coenzymes. 
Chromatography of Serum 
After thawing the frozen samples, the super¬ 
natant was separated from the gelatinous precipitate 
and then filtered. Sufficient potassium phosphate 
pH 6.0 was added to make the filtered supernatant 
0.1 M with respect to potassium phosphate, and the 
sample was chromatographed in the manner described. 
Chromatography of Urine 
One hundred ml of the refrigerated urine 
were diluted with an equal volume of water and mixed 
for one hour with approximately one-third of the 
A-25 DEAE Sephadex from the column. The Sephadex 
was previously treated with 0.1 M potassium phosphate 
buffer pH 6.0 which contained 0.2 M 2-mercaptoethanol. 
The Sephadex-urine mixture was then poured to 
complete the top third of a 0.9 x 30 cm column, 
the bottom two thirds of which was packed with Sephadex 
unexposed to the urine sample. The sample was then 
chromatographed in the manner described. 
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Figure 4. Idealized elution pattern of the folate 
coenzymes obtained from this chromatographic system. 
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DETERMINATION OP RADIOACTIVITY 
The radioactivity of samples was determined 
by liquid scintillation counting in a fluid prepared 
by combining two solutions, one consisting of 100 mgm 
of POPOP, £ £-bis-02-{5-phenyloxazolyl)j - benzene^ , in 
2 liters of toluene and the other of 8 Gm of PPO, 
2,5 - diphenyloxazole, in one liter of absolute ethanol. 
COUNTING 
All counting vials were prepared by adding 
0.5 ml of the sample to be counted to 15 ml of the 
counting fluid. Samples were counted for 10 minutes 
in a Packard Liquid Scintillation Counter. The 
scalers were set so that one counted carbon-14 but 
not tritium; the other counted all the tritium plus 
a constant small fraction of the carbon-14 disintegrations. 
Urine 
Duplicate 0.5 ml samples were removed from 
the refrigerated urine and counted as described. 
Plasma 
Three ml of the refrigerated plasma was 
added to one ml of 10% perchloric acid and the sample 
was centrifuged. Duplicate 0.5 ml samples of the 




A sample calculation for the disappearance 
from the plasma is as follows: the duplicate counts 
(both in the tritium and carbon channel) were 
individually averaged and the separate backgrounds 
subtracted. These values were converted to 
disintegrations by reference to an External 
Standardization Channels Ratio count and to a 
calibrated chart which correlated that Ratio with 
counting efficiency. 
The simultaneous counting of both 
tritium and carbon-14 resulted in the spillover of 
a constant fraction of the total carbon-14 counts 
into the tritium channel. The disintegrations 
due to tritium were corrected for this spillover. 
The corrected disintegrations due to each radio¬ 
nuclide were expressed as disintegrations per liter 
of plasma and in turn, as a percent of the total 
radioactivity administered in the form of 
radiolabeled 5-MeTHP. 
The calculations involving the urinary 
excretion were similar. The total disintegrations 
in the urine sample were determined and expressed 






Plasma disappearances of the radiolabels 
for the early time periods before and after MTX 
therapy are illustrated in Figures 5 and 6. 
The plasma disappearance appears to 
consist of two exponential processes--a rapid 
initial disappearance followed by a longer slower 
phase. Following MTX therapy, the initial faster 
phase of plasma disappearance appeared to be 
shortened. Also after MTX therapy, the plasma 
levels begin higher and are maintained at higher 
levels for the first few days, only gradually 
approaching the levels obtained before therapy. 
Before therapy, the percent of carbon-14 
of the administered dose reduces to zero at 63 
hours and remains there. At 24 hours, the tritium 
reduces to 0,2% of the administered dose and 
remains at this level until 114 hours, when the 
last sample was drawn. 
Following MTX therapy, at least 96 hours 
is required before the carbon-14 level falls to zero. 
The time required for the tritium to decrease to 0.2^ 
of the administered dose is not greatly affected, 




Figure 5. Plasma disappearance 
and after MTX therapy.- (Patient 
Figure 6. 
of tritium before 
1). 
Figure 6. Plasma disappearance of carbon-14 before 
and after MTX therapy. (Patient 1). 
■51 > , 
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Ratio of Radiolabels in Plasma 
Figure 7 illustrates the ratio of tritium 
to carbon-14 in the plasma for patient 1 over a 24 
hour time period. 
After the original administration of 
■z 14 
5-MeTEF the plasma ratio (JE/ C) was seen to 
increase greatly with time. In patient 1, the 
ratio was still increasing at 114 hours and had 
become so high that it was not possible to 
measure it. Measurements for patient 2 were 
terminated at 48 hours, but at that time were 
increasing similarly to patient 1. 
When 5-MeTHF was administered following 
MTX therapy, the ratio did not begin to increase 
at once. Rather, an Increase was noted but only 
after 48 hours following the administered dose. 
At 100 hours, when the studies were concluded, 
both ratios were still rising. 
An increase in the ratio was noted both 
before and after MTX therapy. Before therapy, it 
began in a few hours after the administered 
5-MeTHF. Following therapy, it was delayed 48 hours. 
Chromatography of Serum 
TABLE III summarizes the results of the 

28. 
Figure 7. Ratio () of plasma radioactivity - 
divided by the original ratio (^H/^C) of administered 
radioactivity at the indicated times both before and 
after MTX therapy. (.Patient 1),. 

29. 
TABLE III. Results of the chromatography of serum. 
The percentages express the ratio of tritium of the 
particular peak to the total tritium added to the 
3 14 
column. The ratios express the ratio of H to C 
of that particular peak. The time indicates the 
interval between the first administered dose of 
5-MeTHF and the time of plasma sampling, or the 
interval between the second administration of 5-MeTHF 
and the time of serum sampling. 
(Patient 1) 
BEFORE MTX AFTER MTX 




V14c) 1.8 2.3 

















BEFORE MTX AFTER MTX 




Vl4c) 17.6 3.62 














chromatography of the serum both before and after 
MTX therapy. 
Two radioactive peaks were consistently 
obtained from chromatography of the serum. The 
first peak is unidentified and may be similar to 
peak A of the urine chromatography (vide infra). 
Peak C in the serum corresponded to peak C in the 
urine and has been tentatively identified as 5-MeTKF. 
The radioactive peak found in urine but not in the 
serum is thought to be p>-ABG, a possible degradation 
product of THF. The amount of radioactivity found 
in peak A is decreased after MTX administration and 
the ratio (^H/lZ|"C) generally increases with time. 
The elution pattern obtained from the 
chromatography of the serum is similar to the 
chromatography of the urine except for the jd~ABG 
peak. (See section on the chromatography of urine.) 
URIKE 
Urinary Excretion Rates 
Figures 8 and 9 illustrate the urinary 
excretion rates of the radiolabels either before or 
after MTX therapy. 
Sven before MTX therapy, the labels are 
quickly excreted into the urine. The periods studied 
often exceeded 100 hours, and within the first 6-8 hours 

31. 
Figure 8. The appearance- of radioactivity in the urine. 
Each label is expressed as'a cumulative percent of the 
administered dose. The period of MTX infusion is 













Figure 9. The appearance- of the radioactivity in the 
urine. Each label is expressed as a cumulative 
percent of the'administered dose. The samples were 
collected following MTX therapy. (Patient 1). 

33. 
of this period, half of the total excreted radio- 
activity was already present in the urine. This is 
indicative of the rapid initial excretion followed 
by a small percent (less than 2%) being excreted each 
day thereafter for the duration of the study. This 
slower, more prolonged rate was constant. 
In patient 1, the urinary excretion of the 
previously administered radiolabels was monitored 
during a MTX infusion. An increase in the rate of 
excretion of a tritium labeled compound into the 
urine was noted (Figure 8). Following this 
increased initial excretion, the rate of excretion 
leveled off to less than 2% of the administered dose 
being excreted each day - similar to the results 
obtained before MTX. 
In both patients, the urinary excretion 
of the radiolabels was increased after MTX therapy. 
In patient 1, the increased excretion of radiolabels 
was less than doubled; but in patient 2, the excretion 
of radiolabels increased four times. This greater 
increase could be due to the fact that patient 2 
received the second dose of 5-MeTHF only 24 hours 
after the termination of MTX while patient 1 
received the 5-MeTHF 48 hours after MTX therapy. 
Of interest, patient 2 excreted a larger 
percent of carbon-14 both before and after MTX therapy 

34. 
as compared to patient 1 who excreted a larger 
percent of tritium. The significance of this is 
presently unknown. 
Ratio of Radiolabels in the Urine 
Before the administration of MTX, the ratio 
(^H/^C) remained close to the original administered 
ratio. Only during the administration of MTX did 
the ratio increase sharply. These results are 
illustrated in Figure 10. 
Similarly, after the second administration 
of 5-MeTHF following MTX therapy, the ratio remained 
close to or slightly less than the originally 
administered ratio. 
Chromatography of the Urine 
The results of the chromatography in the 
urine from patients 1 and 2 both before and after 
MTX therapy are shown in TABLE IY. Unlike the two 
peaks obtained from the chromatography in the serum, 
three peaks were consistently obtained from the 
urine. The percent of peak A increases with time. 
Relative to the recovered percentages of the other 
peaks, peak A tended to decrease after MTX therapy. 
Before MTX therapy, peak C increases with time 
and following MTX therapy the percent of peak C in 
the urine is increased. 

35. 
Figure 10. The ratio (^H/l4C) of the indicated 
urine samples divided by the ratio (^H/^^G).of the 
original sample. The■time■interval is before and 




TABLE IV. Results of the chromatography of the 
representative urine samples. The percents express 
the ratio of tritium of that particular peak to 
the total tritium added to the column. The ratio 
3 14 
indicates the ratio of H to C of that particular 
peak. Time indicates the interval after the original 
administration of 5-MeTHF and the sample or the 
interval between the second administration of 
5-MeTHF and the sample before or after MTX therapy. 
(Patient 1) 
BEFORE MTX AFTER MTX 
Time 2 Hours 8 Hours 2 Hours 10 Hou: 
Original administered 
ratio (^h/^C) 1. 85 2, «35 
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In each case the sum of these three peaks 
represented less than the total applied radioactivity. 
The missing fractions may have remained on the 
column, may have come straight through the column, 
may have been degraded to products other than p-ABG, 
or may have overloaded the column. 
Figure 11 is a representative chromatographic 
elution pattern of a urine sample. 

38. 
Figure 11. Representative chromatographic elution 
pattern of the urine. The three peaks are lettered 
A, B, and C respectively. The shaded areas at the 
top of the graph represent the elution position 
of the markers. 
































The two phase plasma disappearance curves 
of 5-MeTHP are similar to that reported for folic 
acid at approximately the same administered dose. 
The initial rapid phase may be due to uptake of this 
compound by tissues, mainly liver, kidney and perhaps 
bone marrow. The slope of the second portion of 
each of the plasma disappearance curves is less 
steep than the first portion. The second phase 
may predominantly represent urinary clearance of 
this compound and consequently be dependent upon 
renal function. 
In both patients studied, the plasma 
clearance of radioactivity was slower following 
MTX therapy. Compared to the levels of radioactivity 
which were obtained by the administration of 5-MeTHF 
prior to MTX therapy, plasma levels were initially 
higher; but after 2 to 3 days, they gradually fell 
to the same levels. Using the method of Spray ejt al. 
(38), the physiological distribution of 5-MeTHF 
was determined from the data both before and after 
MTX therapy in patient 1 at the two hour period. 
If MTX does restrict the transport of 5-MeTHF into 
cells, the distribution of 5-MeTHF should be greater 
in the absence of MTX; and it is, by 1.4 times. 

41. 
This data is consistent with the interpre¬ 
tation that the partition of 5-MeTHF out of the 
extracellular fluid and info the cells is reduced 
by MTX. 
3 
The ratio of plasma H radioactivity to 
■^C radioactivity rose with time in each patient 
following the first administration of 5-MeTHF. 
This would be consistent with the belief that the 
administered 5-MeTHF enters cells and is metabolized; 
14 
consequently there would be a loss of the C-labeled 
5-Methyl from the 5-MeTHF. If the parent molecule 
were to re-enter the plasma, after the loss of the 
carbon-14, the ratio would increase as it does. This 
increased ratio indicates that the methyl adduct 
has been transfered (e.g., to homocysteine to yield 
methionine) and may have been replaced by another 
non-labeled one-carbon adduct. This increased ratio 
was not noted following MTX therapy until 48 hours 
later and is consistent with the other data which 
indicates that there is inhibition of cellular 
uptake of 5-MeTHF by MTX. 
Following chromatography of the serum, 
two radioactive peaks were consistently obtained. 
5 14 
The first peak (peak A) contained both H and 0 and 
was eluted earlier than the 10-formylTHF position. 
If has not yet been identified. The proportion of 
radioactivity in peak A was less After MTX therapy. 

42. 
Presumably, after MTX, the administered 5-MeTHF was 
unable to enter the cells to be converted to this 
derivative. 
The second doubly radiolabeled serum peak 
(peak 0) was eluted at the 5-MeTHF position and 
almost certainly represented both unchanged 5-MeTHP 
and also any metabolized coenzyme which had lost 
the labeled carbon and subsequently gained a non- 
labeled carbon in the 5 position. 
The increased ratio (^H/^Q) of this peak 
relative to the administered ratio indicates that 
the labeled 5-MeTHF group has been replaced to 
some extent by a non-labeled 5-methyl group. 
Following MTX therapy, this ratio does not increase. 
URIKE 
Most of the urinary excretion occurred 
within the first 6-8 hours, a finding which is 
similar to the data obtained for folic acid (16); 
however, data comparing identical doses are not 
available. 
The interval between the completion of MTX 
therapy and the second administration of 5-MeTHF 
was 24 hours in patient 2 and 48 hours in patient 1; 
and following MTX the urinary excretion of radio- 
labels by patient 2 was greater than that by patient 1. 
From these data, it appears that MTX also exerts 
an effect on the urinary excretion of 5-MeTHF. 

43. 
The displacement of tritium into the urine 
following the administration of MTX is shown in 
Figure 8. This displacement was not accompanied by 
a corresponding increase in plasma radioactivity; 
or should there have been such an increase, it was 
too small to be detected. 
It has been suggested (19) that this 
increase in urinary radioactivity may represent 
displaced folates which are being stored within the 
renal tubules. Unfortunately, the low level of 
radioactivity prevented identification of this 
displaced tritium, but there is no detectable 
increased quantity of urinary carbon-14 simultaneously 
excreted. This displaced compound could be 5-MeTHF 
which had been formed in vivo from an unlabeled 
methyl group and tritiated THF; the latter could 
have resulted from the metabolism of the administered 
5-MeTHF. McLean (39) found that following the 
intravenous administration of tritium labeled 
folic acid, 25-33% of the total folate displaced 
was in the form of unlabeled 5-MeTHF. (However, 
in patients with megaloblastic anemia, some of the 
5-MeTHF excreted was labeled indicating a more rapid 
metabolism in folate deficiency states.) 
Three radioactive peaks were obtained from 
the chromatography of the urine. The first peak 




The second radioactive peak (peak B) 
found in the urine was not present in the serum and 
was tentatively identified as p-ABG or a compound 
closely related to jd-ABG. This identification could 
be made by the co-chromatography of this radiolabel 
14 
with known £-ABG and by the absence of C from the 
radioactive peak. It may result from the oxidative 
degradation of reduced folates following exposure 
to air (40). Since no radioactivity was associated 
with the jd-ABG peak in the serum, the jo-ABG present 
in the urine samples may have been formed in the 
urine on standing, despite the addition of 2- 
mercaptoethanol to the samples. Alternatively, 
the 2-ABG may have been formed in vivo prior to 
excretion, and its excretion may have been very 
rapid. 
The third peak (peak C), tentatively 
identified as 5-MeTHF, was increased in both 
patients following MTX. This again indicates that 
MTX is able to block the availability of serum 
5-MeTHF for intracellular metabolism, presumably 




The active diastereoisomer of 5-methyl- 
"^C-tetrahydrofolate-3’, 5* - ^H has been administered 
rapidly I.V. at 5 ug/kg to subjects with solid 
tumors both before and after MTX therapy. 
Before MTX, plasma disappearance of both 
radiolabels was rapid and biphasic. From 10-20% 
of the radioactivity administered was excreted in the 
urine within the first 6-8 hours; amounts less than 
2% per day were excreted thereafter. Some 24-48 
hours following cessation of MTX infusion therapy, 
plasma disappearance was slower and urinary excretion 
was greater than before therapy. 
Chromatography of serum obtained at 30 
minutes and at 4 hours after 5-MeTHF administration 
showed that greater than 50% of the radioactivity 
was unchanged 5-MeTHF. Chromatography of urine 
at 2 and 4 hours showed that less than one half 
of the radioactivity excreted in the urine was 
5-MeTHF, probably due to its breakdown in the urine 
since a large proportion of the urinary radioactivity 
was identified as the breakdown product p_-ABG„ 
Following MTX therapy a larger proportion of the 




An unidentified doubly labeled derivative 
was found in both serum and urine. The data showed 
that its formation was increased with time and 
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